ZGC GROUP’s Investee GRIT Biotherapeutics Receives U.S. IND Approval for GT101


  • HOME

  • 2026-11-11

  • click:

  • Font size:bigmediumsmall

Recently, GT101, a tumor-infiltrating lymphocyte (TIL) therapy independently developed by GRIT Biotherapeutics, a direct investee of ZGC GROUP, received approval for Investigational New Drug (IND) application in the United States. The IND covers the use of GT101 in combination with a PD-1 inhibitor as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This represents another milestone for the combination therapy, following its implied approval by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in June 2026.

Founded in 2019, GRIT Biotherapeutics is an innovation-driven, late-stage clinical biopharmaceutical company pioneering next-generation immunotherapies for patients with cancer and autoimmune diseases worldwide. The company has established multiple proprietary technology platforms in China and the United States, as well as a diversified R&D pipeline comprising multiple candidate products. In July 2025, ZGC Capital invested in GRIT Biotherapeutics, providing capital support for the company’s innovative R&D efforts.